Analystreport

ProQR Therapeutics N.V. (NASDAQ: PRQR) had its price target raised by analysts at Leerink Swann from $10.00 to $12.00. They now have an "outperform" rating on the stock.

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com